Frazier Healthcare Ventures was founded in 1991 and is based in Seattle, WA. The firm has $2.2 billion of assets under management, and closed a new $525 million fund in 2016. Frazier currently has two investment strategies; growth-stage investments in healthcare and pharma service providers (these investments focus on companies with $5-30m EBITDA), and venture-stage investments in life science companies. Frazier’s venture allocations have initial sizes of $5m or higher, with the potential for allocations of up to $20m over the life of an investment. While Frazier primarily invests in companies based in or with significant operations in the USA and/or Canada, the firm will also consider opportunities in Europe. In addition to growth and venture-stage investments, Frazier also engages in company creation. The firm is a lead investor in most of its deals.
Frazier Life Sciences only invests in therapeutics, with a focus on asset-based companies. Frazier typically prefers to invest in companies with products which are 6-18 months away from bringing a product candidate into Phase I clinical trials, but may consider investing in assets that are earlier or later than that. The firm invests in all therapeutic areas and all modalities.
Frazier Healthcare Ventures has no fixed requirements for companies or management teams, but looks for strong teams that lead companies that can make use of over $10m in capital; companies with smaller capital needs are not of interest. Frazier can invest in both privately-held and public life science companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based Investment Firm Makes Both Venture & Growth Stage Investments, Focusing Exclusively on Therapeutics
17 AugHot Investor Mandate: Early-Stage Venture Fund Managed By Top VC Firms Seeks Novel, Disruptive Medtech and Digital Health Companies in USA & Europe
17 AugA newly established, early-stage venture fund backed by a sole strategic LP and managed by leading VC firms is actively seeking new investment opportunities. The LP’s decision to invest in the fund reflects the company’s vision of developing disruptive, cost-saving healthcare solutions, which closely matches the vision of the investment team. The firm focuses on US, Europe, and Israel-based companies.
The firm is dedicated to early-stage investing in novel, disruptive medtech and digital health companies that can transform hospital care to lower-cost settings such as the home and health clinics. Areas of particular interest include non-invasive therapeutic medical devices, monitoring technologies for effective chronic disease management and preventative technologies, and is open to devices of all regulatory pathways.
The firm is looking for technologies supported by strong clinical hypotheses that can cost-effectively address large problems in the current healthcare system. The firm is open to working with all kinds of management teams in the US, Europe or Israel. The firm has access to an international network and resources that can be leveraged to support company growth.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: USA-Based VC Actively Invests in Novel Therapeutic Assets Starting from Late Pre-Clinical Stage, Opportunistic Towards Indication
17 AugA life sciences venture capital firm based in the US is focused on early and growth-stage biotech and pharma companies. The firm has more than $350M assets under management. Initial investments typically range from $2M-$20M and are usually in the form of equity, but may use convertible notes in select situations. The firm looks to take a meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs of Boston and San Francisco.
The firm focuses on therapeutic companies within the biotech sector. The firm is mostly opportunistic in terms of technology type and indication area; however, the group prioritizes companies developing assets with unique mechanisms of action that address unmet medical needs. The firm typically invests in companies ranging from late preclinical to Phase 2 clinical trials stage. The firm does NOT invest in diagnostic, device, digital health, or healthcare IT companies.
The firm has no strict company or management team requirements, but usually requires a board seat along with an investment to allow for active participation and collaboration with the company during development.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Growth Equity Firm Invests Up to $100M in Life Science & Healthcare Companies Close to Commercialization
17 AugA healthcare-focused Growth Equity firm currently manages $1 billion and provides $20-100 million of equity capital per company over the life of the investment. With offices in the US and UK, the firm is primarily looking for companies throughout North America and Europe.
The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, life sciences tools, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is open in terms of indications.
The firm looks for management teams that are very willing to work alongside them, and the firm generally looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Surge in Family Offices: Investing in Healthcare
10 AugBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series
In the ever-evolving finance and investment landscape, family offices have emerged as key players with the potential to drive significant change. These private wealth management firms, entrusted with managing the financial affairs of affluent families, have diversified their portfolios to include investments in a wide array of sectors. One sector that has garnered substantial attention in recent years is healthcare. The intersection of wealth preservation, a family’s medical health profile, and social impact have led many family offices to focus on investing in healthcare, a decision that promises financial returns, improves family legacy, and impacts global well-being.
LSN Collaboration with Stetson Family Office in 2019
LSN launched the Global Family Office BioForum in 2019 in collaboration with the Stetson Family Office to match Family Offices with angel groups, early-stage VCs, and KOLs to help identify and vet early-stage healthcare investment opportunities. This collaboration was an extension of Chuck Stetson’s visionary initiative on educating family offices to understand how they can impact chronic diseases like Alzheimer’s, Cancer, and Diabetes/Obesity and tackle big global healthcare issues through his Healthcare Impact Foundation. Over the years, the Global Family Office BioForum has witnessed many of these relationships fostered at LSN’s RESI partnering events grow into strategic alliances and investment syndicates that have helped Family Offices move into the early stage healthcare arena.
The Dynamics of Family Offices
Family offices, by their structure, cater to the unique financial needs of high-net-worth families. With a long-term perspective, they prioritize wealth preservation, growth, and the passing down of wealth to future generations. This approach aligns well with the characteristics of the healthcare sector, which, given its essential nature, presents a range of investment opportunities with the potential for both social impact and financial gains. New drug development can take a decade or more and cost hundreds of millions of dollars, while devices, diagnostics, and digital health technology can be developed in three to five years for five to 15 million. This breadth of choice allows a family office to execute its financial, healthcare, and social impact goals.
Why Healthcare?
As I have stated in the past, planet Earth is in the golden age of life science. Like other investor classes, family offices want a high return rate based on a timeline that matches their money management goals. The healthcare industry is undergoing rapid transformation, driven by technological advancements, changing demographics, and evolving consumer expectations. These shifts create fertile ground for investment, with opportunities that span pharmaceuticals, biotechnology, medical devices, telemedicine, healthcare IT, and more. The demand for innovative solutions to global health challenges is greater than ever, and family offices are positioning themselves as key contributors to this transformation.
Balancing Profit and Purpose
Family offices are uniquely positioned to balance profit with purpose. Investing in healthcare allows them to pursue financial returns and contribute to improving healthcare access, quality, and affordability. Many family offices see healthcare investments to align their financial goals with their desire to positively enhance their family legacy and society.
Driving Innovation
One of the remarkable aspects of family offices’ involvement in healthcare is their ability to drive innovation. By injecting capital into early-stage startups and research initiatives, family offices provide crucial support to ventures that may otherwise struggle to secure funding. This backing accelerates the development of groundbreaking therapies, technologies, and services, ultimately benefiting patients worldwide.
Announcing the Global Partnering Campaign, LSN’s Newest Product
10 AugBy Karen Deyo, Director of Product, Israel BD, LSN
Life Science Nation (LSN) is excited to announce that our newest product, the Global Partnering Campaign Salesforce App, is live! This is a new way to access the LSN Investor and Licensing Partner Database, taking the benefits of LSN’s curated data (10 categories of investors from 3,000 firms with 10,000 contacts), and combining it with LSN’s custom-developed fundraising campaign management tool.
What is the difference between the LSN Investor and Licensing Partner Database and the new GPC product?
The GPC product is a Salesforce App that has to be downloaded off of the Salesforce AppExchange and installed into the company’s Salesforce account. The LSN Investor and Licensing Partner Database gives you access to the same content without a subscription to Salesforce.
Do I need to subscribe to Salesforce to use the new GPC product?
Yes, this new product is available through Salesforce only. Using a CRM like Salesforce is a crucial tool for managing a fundraising campaign and tracking all of your contact with investors and licensing partners – ensuring no missed opportunities or dropped balls.
What do I need to do to get the GPC App?
If you are not already a Salesforce client, subscribe to Salesforce (Professional license or above required), go the Salesforce AppExchange, and find and install the Life Science Nation – Global Partnering Campaign (GPC) app. Once you have installed the app, you will need to subscribe to the Essential or Premium plan through this link and contact LSN at gpc@lifesciencenation.com for your onboarding with your BD representative. After the onboarding is complete, LSN staff will activate the GPC app, and you can start identifying your Global Target List of investors and licensing partners and begin your outreach!
Click here to watch a demo of the new product!
Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences (CLS)
10 Aug Shikha Sharma |
Interview with Shikha Sharma, Senior Director, Innovation at California Life Sciences
By Caitlin Dolegowski, Marketing Manager, LSN |
 Caitlin Dolegowski |
Caitlin Dolegowski (CD): Please introduce us to California Life Sciences.
Shikha Sharma (SS): California Life Sciences (CLS) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. On behalf of our more than 1,200 member organizations, CLS works to shape public policy, improve access to breakthrough technologies, educate lawmakers, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. In doing so, CLS fulfills its mission to protect and nurture California’s life sciences industry, empowering discoveries that lead to healthier lives around the world.
CD: What type of companies do California Life Sciences consider for membership?
SS: CLS members represent companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. As integral components of a healthy and collaborative ecosystem, CLS also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector.
CD: What stage of fundraising is California Life Sciences looking to support?
SS: The CLS Innovation & Entrepreneurship programs primarily support early-stage companies in fundraising stages from pre-seed to Series A. However, the broader CLS community encompasses members, companies, stakeholders, and pharma industry professionals with accessibility to later stage fundraising know-how and connections. Becoming part of CLS gives you access to a broad network that can directly and indirectly support companies in any stage of fundraising.
CD: Clearly, California Life Sciences, is in California. Though, not all your members are located in California. What are your geographic qualifications?
SS: We don’t have geographic qualifications, per se. CLS welcomes any organization that is looking to access, expand and/or maintain a foothold in what I would consider the most robust life sciences ecosystem worldwide.
CD: What works well for California Life Sciences in being a part of the RESI experience?
SS: As part of our portfolio of entrepreneurship services, CLS seeks to establish partnerships with respected partnering and investor conferences to aid our members in the fundraising journeys. Importantly, opportunities like RESI connects them with Seed and Series B investors, channel and licensing partners.
CD: What other information is important for companies to consider about California Life Sciences?
SS: California Life Sciences’ innovation and entrepreneurship initiatives connect life science startups to the resources needed to help them effectively scale their ventures. Our programs create a platform for accessing business partners, investors, foundations and patient advocacy organizations, peers, and other industry leaders.
Designed to nurture and advocate for emerging and diverse innovators from throughout the state, CLS offers advisory services, positioning for capital tools, access to capital through strategic partnerships and events and US market access resources to help in the development and commercialization of their business.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 